New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:15 EDTMGNXMacroGenics initiates Phase 1 study of MGD006
MacroGenics announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia. MGD006 is a humanized, Dual-Affinity Re-Targeting, or DART, bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
16:17 EDTMGNXMacroGenics presents DR5 DART preclinical data
MacroGenics announced the presentation of pre-clinical data for Dual-Affinity Re-Targeting, or DART, molecules that target DR5 at the 2015 American Association for Cancer Research, or AACR, Annual Meeting in Philadelphia, PA. In addition, MacroGenics' collaboration partner, Pfizer Inc., presented pre-clinical data on a DART molecule that simultaneously targets P-cadherin and CD3. MacroGenics presented a poster titled: "DART molecules with enhanced DR5 agonistic activity for improved cancer cell cytotoxicity." In this poster, application of MacroGenics' DART platform is shown to drive clustering of DR5 on cancer cells resulting in potent anti-tumor activity, including activity in models of cancer stem cells. DR5, or Death Receptor 5, member 10b of the tumor necrosis factor receptor superfamily, is a protein overexpressed in many kinds of tumors, including colorectal, lung, pancreatic, breast and prostate. Ligation of DR5 with its cognate ligand TRAIL or agonistic monoclonal antibodies elicits a pro-apoptotic signal on cancer cells, leading to programmed cell death. DR5 monoclonal antibodies selected from MacroGenics' discovery platform based on favorable normal/tumor binding properties were incorporated into multivalent DARTs. The efficacy of the DR5 DART molecules in mediating cancer cell cytotoxicity is 10-100 fold enhanced compared to that of TRAIL and previously described agonistic DR5-targeted monoclonal antibodies. Based on their enhanced potency and selectivity, DR5-targeting DARTs represent a new class of therapeutics that may overcome limitations of existing DR5-targeted therapeutics. The pre-clinical data support the use of DR5-engaging DARTs to exploit this apoptotic pathway in multiple cancer types.
April 17, 2015
09:07 EDTMGNXMacroGenics management to meet with Oppenheimer
Meeting to be held in Dallas on April 23 hosted by Oppenheimer.
April 14, 2015
07:05 EDTMGNXNeedham to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use